Allergan: Here's Why Ackman and Valeant Want the Botox Maker

Here's what you need to know about Valeant's (VRX) planned $45 billion acquisition of Allergan (AGN),

Apr 22, 2014 at 12:00PM

Weeks after Johnson & Johnson shelved plans to launch a Botox competitor, Allergan (NYSE:AGN) is in the news again.

Hedge fund manager Bill Ackman's Pershing Square has built a nearly 10% stake in Allergan in advance of a potential $45 billion bid by Valeant (NYSE:VRX) to buy the company.

Allergan's shares have jumped since reports of the potential acquisition, pushing Allergan's value above the rumored takeover price. So, let's take a closer look at Allergan and why Valeant is interested in buying it.

AGN Chart

AGN data by YCharts.

Synergies, synergies, synergies
Allergan has a diverse product line that stretches from breast implants to eye drops, but its biggest and best known drug is the wrinkle-reducer Botox.

Allergan sold just shy of $2 billion worth of Botox in 2013, up 12% from 2012, which means Botox represents more than a third of Allergan's total sales.

Botox success has led drugmakers to develop to a wave of competing drugs, including PurTox from Johnson & Johnson's Mentor unit. However, despite previous hopes to launch PurTox, Mentor shuttered the drug's development earlier this month.

While Johnson's abandoned its potential Botox competitor, Valeant continues to battle for Botox market share with Dysport and Restylane. Valeant acquired these Botox alternatives in its $2.6 billion buyout of Medicis Pharma in 2012. That deal also gave Valeant the acne-drug Solodyne.

But consolidating its skin care business with Allergan's isn't the only reason Valeant is interested in owning Allergan.

Allergan's Lumigan, Restasis, and Refresh helped Allergan's opthamology segment post sales of nearly $2.9 billion in 2013, up 7.4% from 2012. That works out to 54% of Allergan's full-year sales last year.

That size and global reach is likely very intriguing to Valeant given it also operates a huge eye care business, thanks in part to its $8.7 billion acquisition of Bausch & Lomb last year.

Sales of Bausch & Lomb products grew 10% year over year in the fourth quarter for Valeant, helping drive Valeant's total 2013 revenue to $5.8 billion and its adjusted earnings per share to $6.24.

Given Valeant's success with Bausch & Lomb, integrating Allergan's significant eye care business offers substantial cost savings and cross-selling opportunity. Valeant will be able to reduce marketing and sales personnel in overlapping markets, and provide its remaining sales team with more products to pitch to accounts.

Fool-worthy final thoughts
Acquiring Allergan would allow Valeant significant cost savings both in its dermatologic and eye care product lines, but additional bottom-line benefits could come from reducing Allergan's R&D budget and leveraging Valeant's friendly tax structure.

Allergan had expected to spend 16.5% of its net sales on R&D this year, and for taxes to account for between 26% and 27% of non-GAAP earnings. Combined, those two line items represented nearly $1.5 billion in expenses during 2013. Valeant would cut that R&D spending to about $300 million, and it expects the effective tax rate on the newly combined company would only be in the high single digits.

Valeant already expects sales of $8.3 to $8.7 billion this year, producing cash EPS of $8.55 to $8.80. And Allergan is guiding for 2014 sales of $6.65 to $6.95 billion, generating $5.36 to $5.48 in EPS. If Valeant is able to close this deal, it expects Allergan will be accretive to its EPS forecast by 25% to 30% this year, and 15% to 20% per year thereafter.

Given all the potential synergies, Valeant could become a far bigger and more profitable company, but it will have to convince Allergan's other shareholders to sell first.

6 stock picks poised for incredible growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his six carefully chosen picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

Todd Campbell has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson and Valeant Pharmaceuticals. The Motley Fool owns shares of Johnson & Johnson and Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information